A partnership agreement has been entered by Haselmeier (a Swiss-based developer and manufacturer of self-injection devices) and Common Sensing (a Cambridge-based smart injector monitoring and support solution company) for the development of smart connected monitoring and support solutions for users of injectable medicines.
Smart injectables
As a part of this partnership, Haselmeier’s subcutaneous drug delivery injection systems for self-administration will be combined with Common Sensing’s Gocap injector monitoring technology, creating a smart disposable injector pen platform, to be available in 2019. This new platform will be sold by Haselmeier.
“Haselmeier is excited about the collaboration with Common Sensing,” stated Paul Jansen, Haselmeier senior advisor and board member. “Both companies have recognised how complementary their technologies were and how much this partnership will provide value for both Companies and patients. The joint relationship we have built will enable Haselmeier and Common Sensing to rapidly bring a unique connected pen solution on the market.”
“This partnership is a fantastic, market shaping opportunity to merge the leading edge, Haselmeier D-Flex injector with our Gocap connected health technology in a scalable, commercial platform,” said Kevin Schmid, Common Sensing’s chief operating officer.
“There is a high need to provide patients the means to better monitor the efficacy of their therapy and the injection experience is a crucial moment in a patient’s therapy,” added Frédéric Gabriel, Haselmeier’s chief strategy officer. “The collaboration of Haselmeier with Common Sensing is a smart and fast way to achieve our objective in improving patients’ lives.”